Medical Research
(H12)
990 on File
EICOSANOID RESEARCH FOUNDATION
Financial strength (30%)
72/100
Reliability (20%)
55/100
Effectiveness (25%)
75/100
Impact (25%)
No data yet
CharityAI™ Score
Not yet evaluated
Financial Overview — FY 2023
$20K
Total Revenue
$26K
Total Expenses
$12K
Net Assets
0
Employees
Revenue Sources
Expense Breakdown
Program Expense Ratio
94.8%
Fundraising Efficiency
N/A
Operating Reserve
5.24x
Liability-to-Asset
-6.9%
Revenue Diversification
94.4%
Compared with Peers
FY 2023
Compared with 1,152 similar organizations
(United States, Medical Research, under $100K in expenses), FY 2023.
This organization
Middle half of peers (P25–P75)
Peer median
| Ratio | This org | Peer median | Position (P10 → P90) | |
|---|---|---|---|---|
|
Program expense ratio
Program expenses / total expenses
· higher is better
|
94.8% | 80.3% |
P10P90
|
Above median |
|
Admin expense ratio
Management and general / total expenses
· lower is better
|
5.2% | 12.0% |
P10P90
|
Above median |
|
Fundraising expense ratio
Fundraising expenses / total expenses
· lower is better
|
0.0% | 0.0% |
P10P90
|
Top quarter |
|
Operating reserve
Months of expenses covered by net assets
· higher is better
|
5.2 mo | 37.0 mo |
P10P90
|
Bottom quarter |
|
Liabilities to assets
Total liabilities / total assets
· lower is better
|
-6.9% | 0.0% |
P10P90
|
Top quarter |
|
Revenue concentration
Share of revenue from the largest source
· lower is better
|
94.4% | 100.0% |
P10P90
|
Above median |
|
Revenue growth
Year over year revenue growth
|
-92.4% | -1.6% |
P10P90
|
|
|
Expense growth
Year over year expense growth
|
-92.0% | -3.6% |
P10P90
|
|
|
Surplus margin
Surplus as a share of revenue
|
-31.6% | 12.7% |
P10P90
|
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2023 | $20K | $26K | $12K | 94.8% | 0 |
| 2022 | $266K | $332K | $18K | 97.5% | 0 |
| 2021 | $152K | $20K | N/A | — | 1 |
Donor Reviews
Write a ReviewNo reviews yet
Be the first to share your experience with this organization.